Skip to content

TXMD - TherapeuticsMD, Inc. - AlphaYou

Discover Compare Pricing

Sign in Sign up

Home Smart money Buy calls Analyze

Back to stock searchT

TherapeuticsMD Inc

TXMD · NASDAQ

Save to watchlist

Price is syncing

Reported smart-money activity for this stock is still below.

T

TXMDTherapeuticsMD Inc

Overview

No source-backed view yet. This page is available for price, fundamentals, and future receipts as coverage warms.

Key stats

Aug 21

52-wk high: $2.95
52-wk low: $0.99
Prev close: $2.17
Mkt cap: $23.5M
Fwd P/E: 2.3x
Beta: 0.64

Smart money

7 funds hold a position.

Real smart money

Funds holding this stock

7 holders

Combined position$836K

JS
Jim Simons
Q2 2026 13F
$324K
position
CI
Citadel
Ken Griffin · Q2 2026 13F

Earnings

Earnings

Results versus expectations

Documents

Quarterly report10-Q Annual report10-K

Financials

Fundamentals

Is the business strong?

This company is not yet profitable.

Net margin: -6.6%
Forward P/E: 2.33
Market cap: $23M

Valuation

P/S7.19
P/B0.85

Quality

Operating margin-32.2%

Technicals

Technicals

Price structure

No data yet

Technicals sync when verified market data is available. No sample data is shown.

Company

Symbol: TXMD
Exchange: NASDAQ
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC
Market cap: $23.50M
Beta: 0.64

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Research hubs
About
Editorial policy
Methodology
Source coverage
Corrections

Privacy
Terms
Refunds
Disclaimer

© 2026 AlphaYou. All rights reserved.Not financial advice. Do your own research. Informational data only; past performance does not predict future results.

P/S

7.2x

P/B

0.9x

Profit margin

-6.6%

Op margin

-32.2%

ROE

-1.1%

$190K

position

BR

BlackRock

Q2 2026 13F

$254K

position

4 more holders

Lite opens all of them for $16.50/month, paid yearly.

Unlock all 4 holders

Coverage gaps for TXMD

No recent insider trade
No recent Congress trade
No recent market-voice mention

The latest quarter is still settling.

A verdict appears once the reported figure is final

Next report

What the street expects next

ROE

-1.1%

ROA-2.9%

Growth

Beta0.64